Seeking Alpha

An FDA panel is due to vote this week on whether to lift the restrictions on Avandia,...

An FDA panel is due to vote this week on whether to lift the restrictions on Avandia, GlaxoSmithKline's (GSK +0.3%) former blockbuster diabetes pill whose sales plummeted after the agency said in 2010 that it could only be used only in rare cases due to fears that it caused heart attacks. Following a new positive analysis of old data, two panels will decide whether to remove, modify or leave Avandia's safety restrictions in place, or withdraw the drug entirely.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|